Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment

N Engl J Med. 2022 Sep 15;387(11):1045-1047. doi: 10.1056/NEJMc2206449. Epub 2022 Sep 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents* / adverse effects
  • Antiviral Agents* / therapeutic use
  • COVID-19 Drug Treatment*
  • Drug Combinations
  • Humans
  • Lactams* / adverse effects
  • Lactams* / therapeutic use
  • Leucine* / adverse effects
  • Leucine* / therapeutic use
  • Nitriles* / adverse effects
  • Nitriles* / therapeutic use
  • Proline* / adverse effects
  • Proline* / therapeutic use
  • Recurrence
  • Ritonavir* / adverse effects
  • Ritonavir* / therapeutic use
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Drug Combinations
  • Lactams
  • Nitriles
  • nirmatrelvir and ritonavir drug combination
  • Proline
  • Leucine
  • Ritonavir